Epstein Secrets

ovid-vaccine-then-scholars-clashed- over-money-11603300412> (10/21, Al, Woo, Subscription Publication, 7.57M) reports on the controversy surrounding the University of Oxford's vaccine program, while the AP <https://apnews.corn/article/vaccine-kids- testing-school-covid-19-37fdcb046044483d256c612d4432d7c9> (10/21, Neergaard)

.com/article/us-health-coronavirus-brazil-vaccine/astrazeneca-covid-19-vaccine- trial-brazil-volunteer-dies-trial-to-continue-idUSICBN2762MO> (10/21, Burger) reports that "a source familiar with the matter told Reuters that the trial would have been suspended if the volunteer who died had received the C

11/22, Paton, 4.73M) reported that "the stakes for lower- and middle-income nations are EFTA00137336 immense," given that "the shot developed with the University of Oxford accounts for more than 40% of the supplies going to those countries, based on deals tracked by London-based research firm Airfinity Ltd." Moreover,

ealth- coronavirus-astrazeneca-oxford/decades-of-work-and-half-a-dose-of-fortune-drove-oxford-vaccine-success- idUSKBN2832NC> (11/23, Smout, Kelland, Burger) reports AstraZeneca "said it was a minor mistake that made the team realise how they could significantly boost the shot's success rate, to as much

ne. Bloomberg (11/22, Paton, 4.73M) reported that "the stakes for lower- and middle-income nations are immense," given that "the shot developed with the University of Oxford accounts for more than 40% of the supplies going to those countries, based on deals tracked by London-based research firm Airfinity Ltd." Moreover,

g two full doses one month apart was 62% effective." Combined, the data indicated "an average efficacy rate of 70%." Reuters (11/23, Smout, Kelland, Burger) reports AstraZeneca "said it was a minor mistake that made the team realise how they could significantly boost the shot's success rate, to as much

f cases during the colder months." The Wall Street Journal (10/21, Al, Woo, Subscription Publication, 7.57M) reports on the controversy surrounding the University of Oxford's vaccine program, while the AP (10/21, Neergaard) reports that "the global hunt for a COVID-19 vaccine for kids is only just beginning - a lagging s

dy in Brazil. ... Its trial here in the US was put on hold last month after a volunteer in Europe developed neurological symptoms." Reuters (10/21, Burger) reports that "a source familiar with the matter told Reuters that the trial would have been suspended if the volunteer who died had received the CO